Search | Clinical Trials Finder

Conditions: Peanut Allergy
Interventions: ASP0892, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 7
States / cities: Little Rock, Arkansas • Mountain View, California • Chicago, Illinois + 4 more

Conditions: Rotavirus Infection
Interventions: P2-VP8 subunit rotavirus vaccine, placebo; Biological · Other
Lead sponsor: PATH; Other
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: JS7 DNA vaccine, MVA/HIV62 vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Birmingham, Alabama • San Francisco, California • Seattle, Washington

Conditions: HIV Infections
Interventions: env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, GLA-SE adjuvant, Placebo; Biological
Lead sponsor: Worcester HIV Vaccine; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Infections, Papillomavirus
Interventions: Gynaecological follow-up, Cervarix, Placebo control; Procedure · Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 28 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 3
States / cities: Iowa City, Iowa • Wichita, Kansas • Wenatchee, Washington

Conditions: HIV Infections
Interventions: EP HIV-1043, EP HIV-1090; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: San Francisco, California • Baltimore, Maryland • Rochester, New York

Conditions: HIV Infections
Interventions: env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, Placebo, GLA-SE adjuvant; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 3 more

Conditions: HIV Infections
Interventions: Sub C gp140 Vaccine, MF59C.1 Adjuvant, Sodium chloride; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID-19 Disease
Interventions: INO-4800, CELLECTRA® 2000, Placebo; Drug · Device
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,307 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 16
States / cities: Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 12 more

Conditions: HIV Infections
Interventions: p24CE1/2 pDNA Vaccine, p55^gag pDNA Vaccine, IL-12 pDNA Adjuvant, Placebo, Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device; Biological · Device
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: San Francisco, California • Decatur, Georgia • Cleveland, Ohio

Conditions: HIV Infections
Interventions: GEO-D03 DNA vaccine, MVA/HIV62B (MVA62B) vaccine, Placebo for GEO-D03 DNA, Placebo for MVA62B:; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 4
States / cities: Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 1 more

Conditions: HIV Infections
Interventions: AIDSVAX B/E Vaccine, DNA-HIV-PT123 Vaccine, Placebo for DNA-HIV-PT123, Placebo for AIDSVAX B/E; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: San Francisco, California • New York, New York • Rochester, New York + 3 more

Conditions: Cytomegalovirus Infection
Interventions: mRNA-1647, Placebo; Biological · Other
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 315 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 9
States / cities: Sacramento, California • Peoria, Illinois • Lenexa, Kansas + 5 more

Conditions: Cytomegalovirus Infection
Interventions: mRNA-1647, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts • St Louis, Missouri • Seattle, Washington

Conditions: COVID-19, SARS-CoV2
Interventions: SAB-185, Normal saline; Biological · Other
Lead sponsor: SAb Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 3
States / cities: Wichita, Kansas • Syracuse, New York • San Antonio, Texas

Conditions: Cytomegalovirus Infection
Interventions: mRNA-1647, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 16 Years to 40 Years · Female only
Enrollment: 7,454 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 181
States / cities: Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 141 more

Conditions: Cervical Intraepithelial Neoplasia Grade 2/3, Human Papilloma Virus Infection Type 16
Interventions: PVX4 Combination Product, Placebo Control; Combination Product · Other
Lead sponsor: PapiVax Biotech, Inc.; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: HIV Infection
Interventions: ADVAX; Biological
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 60 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 2
States / cities: New York, New York • Rochester, New York

Conditions: Healthy
Interventions: VCR-HIVDNA006-00-VP; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: HIV-MAG vaccine, IL-12 pDNA adjuvant, VSV HIV gag vaccine, Placebo, Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device; Biological · Device
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 5
States / cities: New York, New York • Rochester, New York • Philadelphia, Pennsylvania + 1 more

Conditions: HIV Prevention
Interventions: PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)), PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)), Alhydrogel adjuvant, GLA-SE adjuvant, Placebo for DNA Vaccines, Protein Vaccines and Adjuvants; Biological
Lead sponsor: Worcester HIV Vaccine; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: Profectus HIV MAG pDNA vaccine, IL-12, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 13
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 8 more

Conditions: Venezuelan Equine Encephalitis Virus Infection
Interventions: Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate, 0.9% saline placebo; Biological · Other
Lead sponsor: Ichor Medical Systems Incorporated; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: San Diego, California

Conditions: HPV Infection
Interventions: pBI-11 (3 doses), pBI-11 (1 dose), Placebo (2 doses); Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Birmingham, Alabama • Baltimore, Maryland

Search by objective public record fields.

A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus Vaccine

Early Immune Responses to Vaccination - A Substudy to HVTN 205

Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults

Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects

Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults

Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults

Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)

Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure

Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA

Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults

Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults

Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia

Safety and Immunogenicity of a Plasmid HIV Vaccine in HIV Uninfected Adults

HIV-1 Vaccine Test in Uninfected Adult Volunteers

Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults

Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults

Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults

Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers

Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+